5 Einträge gefunden

1. Impact of molecular residual disease post allografting in myelofibrosis patients

   1. Wolschke, C
   2. Badbaran, A
   3. Zabelina, T
   4. Christopeit, M
   5. Ayuketang, Francis Ayuk
   6. Triviai, I
   7. Zander, A

   2017 - Forschungsinformationssystem des UKE
2. Donor choice according to age for allo-SCT for AML in complete remission

   1. Ayuketang, Francis Ayuk
   2. Zabelina, T
   3. Wortmann, F
   4. Alchalby, H
   5. Wolschke, C
   6. Lellek, H
   7. Bacher, U

   2013 - Forschungsinformationssystem des UKE
3. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML

   1. Christopeit, Maximilian
   2. Heiland, A
   3. Binder, M
   4. Zabelina, T
   5. Ayuketang, Francis Ayuk
   6. Horn, C
   7. Haferlach, T

   2013 - Forschungsinformationssystem des UKE
4. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

   1. Kröger, N
   2. Zabelina, T
   3. Klyuchnikov, E
   4. Kropff, M
   5. Pflüger, K-H
   6. Burchert, A
   7. Stübig, T

   2013 - Forschungsinformationssystem des UKE
5. Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors.

   1. Neth, O W
   2. Bacher, U
   3. Das, P
   4. Zabelina, T
   5. Kabisch, H
   6. Kroeger, N
   7. Ayuketang, Francis Ayuk

   2010 - Forschungsinformationssystem des UKE - frei zugänglich